Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Prostatic Neoplasms 11Breast Neoplasms 10Neoplasms 4Osteoporosis 2Melanoma 2Cardiovascular Diseases 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Regional Osteoporosis as a Result of Chemotherapy 1Primary Ovarian Insufficiency 1Polycystic Ovary Syndrome 1Paraganglioma, Extra-Adrenal 1Pain 1Oropharyngeal Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Monoclonal Gammopathy of Undetermined Significance 1Metabolic Syndrome 1Menstruation Disturbances 1Lymphedema 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hematopoietic and Lymphoid System Neoplasm 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Depression 1Cognitive Dysfunction 1

Interventions

lenvatinib 2temsirolimus 1penpulimab 1cabozantinib 1anlotinib 1Vinorelbine 1Temozolomide 1Sirolimus 1Restraint, Physical 1Everolimus 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Paraganglioma, Extra-Adrenal × Absorptiometry, Photon × Clear all
NCT02592356 2024-03-05

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

M.D. Anderson Cancer Center

Phase NA Completed
23 enrolled
CNSEndocrine

Paraganglioma, Extra-Adrenal, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡